Outcome of a third salvage ASCT in multiple myeloma

**Goal:** What is the outcome after a 3rd ASCT in multiple myeloma? Many patients get a tandem ASCT... and relapse 10 years later! Patient population: between 1997-2010; 417 patients with double ASCT

Relapse ASCT (AARA), 72 patients with ASCT Relapse ASCT Relapse ASCT (ARARA).

**Conclusions:** AARA is a valid option. After the 3rd ASCT: ≥ PR=80%; OS=3 years; NRM=18%.

Number of MM transplants 2003-2014

You can help with our Data Quality Initiative

To improve the release data quality in MM of the EBMT registry, the CMWP would like to invite you to participate in our Data Quality Initiatives. Queries were made on the database to identify lacking data regarding relapse and (previous) transplant in MM. Data Quality Initiatives aim to include more patients with complete data. *All future studies would benefit from this DQI* i.e. 3rd auto-transplant (L. Garderet).

Expected data request Plasma Cell Leukaemia (April ‘16)

We need additional information for the primary plasma cell leukaemia: Confirmation of diagnosis (plasma cell count, plasmacytosis), pre-treatment with novel agent, planned strategy, aim, transplant data (performance status, source, donor, conditioning), and follow-up.

Myeloma faculty from educational event (Hamburg, Jan ’16)

You can help with our Data Quality Initiative

To improve the release data quality in MM of the EBMT registry, the CMWP would like to invite you to participate in our Data Quality Initiatives. Queries were made on the database to identify lacking data regarding relapse and (previous) transplant in MM. Data Quality Initiatives aim to include more patients with complete data. *All future studies would benefit from this DQI* i.e. 3rd auto-transplant (L. Garderet).

Number of MM transplants 2003-2014

You can help with our Data Quality Initiative

To improve the release data quality in MM of the EBMT registry, the CMWP would like to invite you to participate in our Data Quality Initiatives. Queries were made on the database to identify lacking data regarding relapse and (previous) transplant in MM. Data Quality Initiatives aim to include more patients with complete data. *All future studies would benefit from this DQI* i.e. 3rd auto-transplant (L. Garderet).

Expected data request Plasma Cell Leukaemia (April ‘16)

We need additional information for the primary plasma cell leukaemia: Confirmation of diagnosis (plasma cell count, plasmacytosis), pre-treatment with novel agent, planned strategy, aim, transplant data (performance status, source, donor, conditioning), and follow-up.

Myeloma faculty from educational event (Hamburg, Jan ’16)

Outcome of a third salvage ASCT in multiple myeloma

**Goal:** What is the outcome after a 3rd ASCT in multiple myeloma? Many patients get a tandem ASCT... and relapse 10 years later! Patient population: between 1997-2010; 417 patients with double ASCT

Relapse ASCT (AARA), 72 patients with ASCT Relapse ASCT Relapse ASCT (ARARA).

**Conclusions:** AARA is a valid option. After the 3rd ASCT: ≥ PR=80%; OS=3 years; NRM=18%.

Number of MM transplants 2003-2014

You can help with our Data Quality Initiative

To improve the release data quality in MM of the EBMT registry, the CMWP would like to invite you to participate in our Data Quality Initiatives. Queries were made on the database to identify lacking data regarding relapse and (previous) transplant in MM. Data Quality Initiatives aim to include more patients with complete data. *All future studies would benefit from this DQI* i.e. 3rd auto-transplant (L. Garderet).

Expected data request Plasma Cell Leukaemia (April ‘16)

We need additional information for the primary plasma cell leukaemia: Confirmation of diagnosis (plasma cell count, plasmacytosis), pre-treatment with novel agent, planned strategy, aim, transplant data (performance status, source, donor, conditioning), and follow-up.

Myeloma faculty from educational event (Hamburg, Jan ’16)